These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3001 related items for PubMed ID: 8582697

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Are all antihypertensive drugs renoprotective?].
    Wolf S, Risler T.
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [Abstract] [Full Text] [Related]

  • 3. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S, Bakir SE.
    Drugs; 2000 May; 59 Spec No 2():25-37. PubMed ID: 11002856
    [Abstract] [Full Text] [Related]

  • 4. Current recommendations for the treatment of hypertension: are they still valid?
    Moser M.
    J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 10. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ, Ishola DA, Akintomide AO, Ajayi AA.
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Use of calcium channel blockers in hypertension.
    Conlin PR, Williams GH.
    Adv Intern Med; 1998 Apr; 43():533-62. PubMed ID: 9506192
    [Abstract] [Full Text] [Related]

  • 13. New treatment guidelines for a patient with diabetes and hypertension.
    Mogensen CE.
    J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH.
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [Abstract] [Full Text] [Related]

  • 17. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K.
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [Abstract] [Full Text] [Related]

  • 18. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.
    Nefrologia; 2008 Apr; 28 Suppl 3():39-48. PubMed ID: 19018737
    [Abstract] [Full Text] [Related]

  • 19. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 151.